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Abstract
Drug resistant tuberculosis (TB) is a major worldwide health problem. In addition to the bac-
terial mechanisms, human drug transporters limiting the cellular accumulation and the phar-
macological disposition of drugs also influence the efficacy of treatment. Mycobacterium
tuberculosis topoisomerase-I (MtTopo-I) is a promising target for antimicrobial treatment. In
our previous work we have identified several hit compounds targeting the MtTopo-I by in sil-
ico docking. Here we expand the scope of the compounds around three scaffolds associ-
ated with potent MtTopo-I inhibition. In addition to measuring the effect of newly generated
compounds on MtTopo-I activity, we characterized the compounds’ antimicrobial activity,
toxicity in human cells, and interactions with human multidrug transporters. Some of the
newly developed MtTopo-I inhibitors have strong antimicrobial activity and do not harm
mammalian cells. Moreover, our studies revealed significant human ABC drug transporter
interactions for several MtTopo-I compounds that may modify their ADME-Tox parameters
and cellular effects. Promising new drug candidates may be selected based on these stud-
ies for further anti-TB drug development.
Introduction
Multidrug resistant tuberculosis (MDR-TB) and extensively drug resistant tuberculosis
(XDR-TB) are becoming a major worldwide health problem. According to the WHO database
(2017), 490,000 drug resistant TB cases were identified in 2016, and an additional 110,000
cases were reported to be susceptible to isoniazid but resistant to rifampicin (RR-TB). By the
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end of 2016, the average proportion of MDR-TB cases, together with XDR-TB was 6.2%. In
the less developed African and Asian areas the observed number of drug resistant cases is espe-
cially high. Co-morbidity of TB with other diseases, including HIV-AIDS is widely observed,
and inadequate antibiotic treatment has also been shown to contribute to TB drug resistance
in patients.
In addition to bacterial factors related to mutations or metabolic adaptation, antituberculo-
tic drug resistance is also shaped by host cell factors [1–3]. Human multidrug transporters of
the ATP binding cassette (ABC) superfamily protect the organism against xenobiotics and
influence the passage of drugs through the cell membranes and tissue barriers. Several antitu-
berculotic agents, including fluoroquinolones and aminoglycosides were shown to be sub-
strates, inhibitors, or inducers of the two prominent human MDR transporters, ABCB1 and
ABCG2 [1, 4–8]. These transporters were shown to play a major role in TB resistance, espe-
cially in cases when the drug treatment is prolonged [9]. MDR transporters are also present in
the surface membrane of alveolar macrophages, shielding surviving Mycobacterium tuberculo-
sis bacteria [10–12]. For these reasons, investigating ABC transporter interactions in the early
stage of anti-TB drug development is indispensable.
To overcome bacterial resistance in tuberculosis, specific mycobacterial targets have been
investigated, among them type-I DNA topoisomerases that catalyze the relaxation of negatively
supercoiled DNA. As opposed to other types of microorganisms, Mycobacterium tuberculosis
(Mtb) has a single topoisomerase-I enzyme (MtTopo-I)[13–15]. According to transposon-
based knock-down experiments, MtTopo-I is essential [16], and specific inhibitors of this
enzyme are considered to be antituberculotic drugs. Our previous work has shown that
MtTopo-I has unique properties and a targeted inhibitor development may result in specific
inhibitors [17]. The compounds investigated in our studies were synthesized by Vichem Che-
mie Research Ltd. and are part of a proprietary collection of designed compounds. As a proof
of concept, we screened Vichem’s compound library (639 compounds) and identified 108
compounds that bind to specific sites of MtTopo-I [18, 19]. Recently, the homology model and
the crystal structure of MtTopo-I has been published, opening the way for rational design of
inhibitors [17, 20–24]. From among the positive hits with benzo(g)-quinoxaline, quinoxaline
or styryl-benzo(g)-quinazoline scaffolds, in the present work we selected 7 compounds for fur-
ther characterization. All these compounds showed significant MtTopo-I inhibitory potential.
Since the interaction of antituberculotic compounds with human MDR transporters may
influence general ADME-Tox properties as well as cellular drug resistance, in addition to
direct MtTopo-I inhibition and bacterial growth inhibition studies we also investigated the
effect of these compounds on the activity of human ABCB1 and ABCG2. We suggest that com-
pounds exhibiting significant Mtopo-I inhibition without mammalian cell toxicity and show-
ing an advantageous ABC transporter interaction pattern may represent new possibilities for
further anti-TB drug development.
Materials and methods
Materials were purchased from Sigma-Aldrich or Thermo-Fisher Scientific (Calcein-AM,
DCV, Presto-blue reagent).
Vichem’s compound library
The Vichem Library compounds (Fig 1) were synthesized by Vichem Chemie Research Ltd.
and are part of a proprietary collection [25], (https://vichemchemie.com/nested-chemical-
library-ncl/). Several Vichem Library compounds were tested previously for their MtTopo-I
inhibitory potential [18], and in this paper a selected set was further characterized. The
Characterization of new topoisomerase-I inhibitors of Mycobacterium tuberculosis
PLOS ONE | https://doi.org/10.1371/journal.pone.0202749 September 5, 2018 2 / 15
Innovation Office) Hungary, KFI_16-1-2017-0232
by NKFIH (National Research Development and
Innovation Office) Hungary, and More Medicines
For Tuberculosis (MM4TB), grant agreement no.
260872 by the European Community Seventh
Framework Programme 7. All fundings supported
experimental research aiming to find new
antituberculotic compounds. Grants supported
collaborative works of authors SE, RH, VN and LO˝
in MM4TB, VN, LO˝, BS, GSZ in DST-TE´T funding,
and AT in KFI_16-1-2017-0232. The funders (DST
Government of India, NKFIH, Europian Community
Seventh Framework Programme 7) provided
supports in the form of research materials and
salaries for AT. Vichem Chemie Research Ltd
provided funding in the form of salaries for PB, IS,
FB, CSSZ, and LO. Collaborations Pharmaceuticals
Inc provided funding in the form of a salary for SE,
ML. The specific roles of these authors are
articulated in the "Author Contributions" section.
The funders did not have any additional role in the
study design, data collection and analysis, decision
to publish, or preparation of the manuscript.
Competing interests: Authors PB, IS, FB, CSSZ,
and LO are employed by Vichem Chemie Research
Ltd. SE and ML are employed by Collaborations
Pharmaceuticals Inc. This does not alter our
adherence to all the PLOS ONE policies on sharing
data and materials.
Abbreviations: ADME-Tox, Absorption-
Distribution-Metabolism-Excretion-Toxicity; ABC
transporter, ATP Binding Cassette Transporter;
DCV, Dye cycler violet; Mtb, Mycobacterium
tuberculosis; MDR, multidrug resistance; MtTopo-
I, topoisomerase I of Mycobacterium tuberculosis;
TB, Tuberculosis.
chemical structures of the selected compounds are presented in Fig 1, showing the benzo(g)-
quinoxaline, quinoxaline or styryl-benzo(g)-quinazoline scaffolds. The synthesis of these com-
pounds has been described in the Supplementary Information (S1 Fig).
In silico docking studies
Docking studies were performed with the MtTopo-I structure, based on the published crystal
structure (PDB ID: 5D5H), and a previous homology model, using Discovery Studio, version 4.1
(Biovia, San Diego, CA), as described previously [18]. Possible binding conformations and bind-
ing site interactions with MtTopo-I were characterized using the Schro¨dinger module, Induced
Fit protocol, (Schro¨dinger Inc. Portland, OR), in which the Glide and Prime stages of searching
best fit to structure had the following parameters: for the first Glide calculation, receptor and
ligand Van der Waals radii were set at a default value of 50% and the maximum number of poses
to report was set at 20. During the Prime stage of the calculation, residues within 5.0Å of the
ligand were refined to better accommodate the ligand. Actual docking of the ligand in the protein
was performed by the Glide module in the second step of the algorithm. The top 20 poses pro-
duced by the first calculation were re-docked in the protein. Docked poses that were within 30.0
kcal/mol of the absolute lowest (relative) pose were then reconsidered, and the best two of each
were kept. Box Center was chosen as centroid of residues: 48, 51, 113, 114, 115, 164, 167, 168, 171,
342, 344, 345, 346, 347, 382, 383, 384, 387, 388, 533, 534, 535, 536, and 591 [18]. (S2 Fig)
DNA relaxation assay
The DNA relaxation assay of supercoiled pUC18 DNA by MtTopo-I enzyme was carried out
as described previously [17, 18]. Briefly, the MtTopo-I enzyme was expressed and purified
from E. coli as described in [17]. Purification of MtTopo-I enzyme was examined by
Fig 1. Chemical structures of the Vichem’s MtTopo-I inhibitors.
https://doi.org/10.1371/journal.pone.0202749.g001
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SDS-PAGE. In DNA relaxation assay one unit of MtTopo-I was preincubated at 37˚C for 15
min with increasing concentrations of investigated compounds from Vichem’s compound
library, in a reaction buffer (40 mM Tris-HCl (pH 8.0), 20 mM NaCl, 5 mM MgCl2, and 1 mM
EDTA). In each experiment, besides the negative and solvent control, a previously established
MtTopo-I inhibitor, norclomipramine, was used as positive control [21]. After preincubation,
500 ng substrate DNA was added and incubated with the enzyme at 37˚C for 30 min. The sam-
ples were electrophoresed in 1.2% agarose gel for 12 h at 2.5 V/cm, stained with ethidium bro-
mide (0.5 μg/ml), and the DNA bands were visualized using a gel documentation system (Bio-
Rad, Hercules, CA, USA). The effects of compounds were tested first at 100 μM, in the next
round positive hits were investigated at 50, 10, 1 and 0.1 μM concentrations. After that, further
concentrations were analyzed optionally between the closest non-effective and effective con-
centrations, to define the concentration of the compound required for complete inhibition (S3
Fig). Assays were repeated for two to three times for each compound.
H37Rv toxicity assay
Selected compounds from the Vichem library (Fig 1) were screened for antimicrobial effects on
a replicating strain, H37Rv of Mycobacterium tuberculosis (Institute Pasteur, Paris), using resa-
zurin reduction microplate assay (REMA). H37Rv was cultivated in Middlebrook 7H9 supple-
mented with 10% ADC, 0.2% glycerol and 0.05% Tween 80, at 37˚C. For plate assays, starting
culture was diluted to 0.0002 at OD600 from a log phase culture. The first screen applied 20 μM
of the compounds in a 7 day-long exposure, in 384-well plate format, against replicating
H37Rv, as described previously [26]. Molecules that showed more than 80% inhibition of resa-
zurin reduction at 20 μM, were further examined to determine their minimal inhibitory con-
centration (MIC) by REMA, with serial dilutions of the tested compounds (20 to 0.04 μM, in
two times dilution series) on 96-well plates, as described in [26] (S4 Fig). All screening was done
with on plate controls (without treatment, solvent control, and rifampicin at 0.1 μg/ml, as a pos-
itive control). Plates were read on a Tecan Infinite M200. Rifampicin was always giving a Z-fac-
tor greater than 0.7. All compounds were measured at least in two independent experiments.
ATPase activity assay for the human ABC transporters, ABCB1 and
ABCG2
The human ABCB1 and ABCG2 proteins were expressed in the baculovirus-Sf9 insect cell sys-
tem. Baculovirus-infected cells were harvested at 72 hours, and the cell membrane fraction was
prepared by mechanical homogenization and differential centrifugation. Human ABC trans-
porter containing membrane vesicles were used in the ATPase activity assay as described ear-
lier [27]. Briefly, the cell membrane vesicle preparation (5 μg membrane protein/sample) was
diluted in an assay buffer containing non-ABC ATPase inhibitors, and the activity assay was
started by the addition of 3.3 mM MgATP. Reference substrates were used in each assay as
indicated in results. The reaction was stopped by adding SDS after incubation for 20 minutes
at 37˚C. Vanadate-sensitive ATPase activity was calculated based on the quantification of inor-
ganic phosphate, as determined by a colorimetric reaction detected by a VictorX3 plate reader
(Perkin Elmer) at 630 nm [28]. Each compound was measured in at least three independent
experiments with three parallels in each case. DMSO, used as solvent of compounds, had no
effect in this assay at the applied concentration.
Cellular transport assays for ABCB1 and ABCG2
For cellular transport assays, mammalian PLB (lymphoblastoid) cell lines, overexpressing
ABCB1 or ABCG2 were used. The parental PLB cell line was purchased from ATCC, and
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ABCB1 or ABCG2 overexpressing cell lines were established by using lentiviral vectors for
human ABC transporters as described earlier in [29]. The transport assays were carried out in
96-well plates. 1x105 cells were incubated in the presence of 0.1 μM Calcein-AM or 1 μM DCV
(Dye Cycler Violet) for the ABCB1 and for the ABCG2 assays, respectively [30, 31]. The assay
was performed in HPMI medium (NaCl 120 mM, KCl 5 mM, MgCl2 0.4 mM, CaCl2 0.04 mM,
HEPES 10 mM, NaHCO3 10 mM, glucose 10 mM, Na2HPO4 5 mM; pH 7.4). Fluorescence of
the cells was detected using a Victor X3 plate reader (for Calcein, exc. at 485 nm, em. at 535
nm) or the Enspire 2300 (Perkin Elmer) plate reader (for DCV, exc. at 360 nm, em. at 440
nm). Kinetics of fluorescence intensity changes were analyzed to determine relative inhibition,
compared to that of a reference agent, providing full inhibition of the ABC transporter. Two of
the Vichem compounds examined (VCC979812 and VCC38977) were not compatible with
the DCV uptake assay because of their intrinsic fluorescence, therefore for these two com-
pounds ABCG2 transport inhibition was characterized by following mitoxantrone uptake.
Mitoxantrone uptake was measured by flow cytometry (BD FACSCanto at 633 nm) by 20 min-
utes incubation in the presence of 7.5 μM mitoxantrone. Each compound was measured in at
least three independent experiments with three parallels in each case. DMSO, used as a solvent
of compounds had no effect in this assay at the applied concentration.
Cytotoxicity assays in mammalian cell lines
The toxic effects of the selected MtTopo-I inhibitory Vichem compounds were tested in three
cell lines, HFF (human foreskin fibroblast), HEK293 (human embryonic kidney) and A431
(human epidermoid carcinoma) cell lines, obtained from ATCC. Establishment of ABC trans-
porter-expressing A431cell lines was achieved by retroviral transduction of the cells as
described previously [32].
For cytotoxicity measurements the cells were seeded in a 96-well culture plate at 5,000 cells/
well (A431, HEK293) or 6000 cells/well (HFF) and incubated overnight. Cells were allowed to
attach to the plate for 24 hours and then serially diluted drugs were added at final concentra-
tions ranging from 20 μM to 3 nM, except for the reference compound, irinotecan, which was
tested in the range of 60 μM to 9 nM. After 72 hours of incubation viability was assessed by
PrestoBlue1 assay (Invitrogen). IC50 values were obtained by sigmoidal curve fitting in the
GraphPad Prism software. All experiments were performed in triplicates and repeated at least
in three independent experiments. DMSO, used as solvent of the compounds, had no effect on
viability at the applied concentration.
Results
Compound selection
In silico docking studies on MtTopo-I enzyme and MtTopo-I enzyme inhibition assays were
performed previously for numerous Vichem Library compounds, while in the current study
we characterized a selected set of seven MtTopo-I inhibitor compounds. For the present study
we have chosen the most promising in silico hits with benzo(g)-quinoxaline, quinoxaline, or
styryl-benzo(g)-quinazoline scaffolds. In the current study, by measuring antibacterial effects,
non-desirable toxic effects, and interactions with human ABC multidrug transporters, we
attempted to generate a focused prescreening system for targeted drug development.
In silico docking of selected compounds into the Mt Topo-I structure
As published previously, binding potentials of several compounds from the Vichem’s NCL
library and the FDA drug catalogue were examined by in silico studies that predicted binding
Characterization of new topoisomerase-I inhibitors of Mycobacterium tuberculosis
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of compounds to the MtTopo-I enzyme. These studies used a homology model of MtTopo-I,
refined by a published crystal structure of MtTopo-I, and potential interaction sites were fur-
ther characterized by a machine learning method [18, 24]. Several Vichem Library compounds
as well as clomipramine (previously identified as an inhibitor of MtTopo-I activity), were
docked in the MtTopo-I crystal structure (10.2210/pdb5d5h/pdb) to identify potential interac-
tion sites (S2 Fig).
Representative docking results are shown in the Supplementary material. S2 Fig. shows a
part of the protein structure where key interactions were observed with Arg167 and Arg114 in
MtTopo-I. In the Schrodinger method, "goodness" of drug binding in the protein structure is
characterized by a GlideScore that is an empirical scoring function designed to maximize sepa-
ration of compounds with strong binding affinity from those with little to no binding ability.
Table 1 shows GlideScores for clomipramine and for the Vichem compounds selected for
more detailed biochemical characterization. All selected compounds scored reasonably well in
docking studies, suggesting binding to the investigated site, and all but two of the Vichem
compounds scored more favorably than clomipramine.
Determination of MtTopo-I inhibitory potential
MtTopo-I was expressed and purified from E. coli as described previously [17]. The inhibitory
effect of compounds from Vichem NCL Library on MtTopo-I enzyme activity was investigated
by in vitro DNA relaxation assays. Norclomipramine, a previously established MtTopo-I inhib-
itor, was used as a positive control [21]. Concentrations required for complete inhibition of
the MtTopo-I activity was determined by applying a gradually refined concentration set for a
large number of compounds (Table 2, S3 Fig). Here we present data for the selected set of
Vichem’s compounds (Table 2). Although the MtTopo-I inhibitory potential of the selected
compounds was somewhat different, all compounds completely inhibited MtTopo-I activity
below 20 μM. The most potent inhibitor of this selection was VCC450327, showing complete
inhibition at 0.1 μM.
Antituberculotic potential of selected compounds assessed in H37Rv
growth assay
Antimicrobial potential of Vichem’s topoisomerase inhibitor compounds was tested in a
growth inhibition assay of the virulent H37Rv mycobacterial strain, first at 20 μM concentra-
tions. Growth of the H37Rv strain was monitored over a period of seven days. Four
Table 1. Docking score results for selected Vichem Library compounds.
Identifier Docking
Glide Score (kcal/mol)
VCC340963 -5.019
VCC450822 -4.742
VCC979812 -2.901
VCC450327 -2.628
VCC389777 -2.475
VCC891909 -2.241
VCC478498 -1.614
Clomipramine -2.383
Selected Vichem Library compounds were docked into the 5D5H crystal structure of MtTopo-I in addition to
clomipramine, which has been previously identified as an inhibitor.
https://doi.org/10.1371/journal.pone.0202749.t001
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compounds inhibited the growth of Mtb bacteria below 20 μM, as shown in Table 2, whereas
three compounds in this set, despite structural similarities, were ineffective. The MIC90 values
were determined from dose-response curves, ranging from 20 to 0.04 μM concentrations (S4
Fig). The MIC90 of four examined compounds was between 0.6–10 μM (Table 2, S4 Fig), sug-
gesting efficient in vitro antibacterial effect.
Interactions of selected compounds with human ABC multidrug
transporters
ATPase assay results. As mentioned in the introduction, ABC multidrug transporters
have an important role in ADME-Tox parameters of many drugs and the detailed investiga-
tion of transporter-drug interactions is required in drug development. ABC transporter–drug
interactions can be examined by various assays that show such interactions from different
aspects. ATPase activity and drug transport are coupled processes in human ABC transporters,
and most interacting drugs influence the ATPase activity in a concentration dependent man-
ner. Measuring the inhibition of the active transport of a fluorescent substrate by a test com-
pound is a more sensitive assay, while does not directly show if the test compound is a
competing transported substrate or a non-transported inhibitor. Finally, cellular toxicity can
also be modified by the expression of ABC drug transporters, and for assessing transporter-
drug interactions viability assays can be performed in transporter expressing cells.
In this study ATPase measurements were performed in isolated Sf9 membrane vesicles pre-
pared from human ABC multidrug transporters expressing cells, containing high levels of the
human transporters. In the Sf9 membrane ATPase assay, measuring the vanadate-sensitive
ATPase activity of the transporter provides a simple but efficient tool to characterize the effects
of various drugs [28, 33]. This ATPase activity often has a complex dose-response curve in the
presence of drug substrates, and a considerable basal ATPase activity (without any given drug)
also complicates the assessment of drug effects.
As shown in Fig 2, we examined the effects of the selected Vichem compounds by following
dose-response curves of ATPase activity. The Vmax values, less informative for these
Table 2. Effects of selected compounds from Vichem’s compound library on MtTopoI activity and growth of
H37Rv Mtb strain.
Identifier Complete inhibition of MtTopoI (μM) MIC90 of compounds in H37Rv growth test (μM)
VCC891909 7.5–10 10.4
VCC979812 10 N.I.
VCC389777 7.5–10 N.I.
VCC450327 0.1 N.I.
VCC450822 10.0 5.1
VCC340963 10–25 2.5
VCC478498 10–25 0.6
N.I. means—no inhibition was observed up to 20 μM
Inhibition of MtTopo-I was measured by DNA relaxation assays by gradually refining the concentrations required
for complete inhibition. Bands of relaxed and supercoiled DNA were visualized on agarose gels (S3 Fig). Minimum
concentrations providing complete inhibition are shown in the table. The toxicity of the compounds on the virulent
H37Rv Mtb strain was determined by growth inhibition tests. Growth inhibitory potential of the compounds was
primarily screened at 20 μM and for the effective compounds the minimum concentration providing 90% growth
inhibition (MIC90 value) was determined from dose-response viability curves (20 to 0.04 μM). The dose-response
curves are presented in supplementary figures (S4 Fig).
https://doi.org/10.1371/journal.pone.0202749.t002
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interactions, were determined from curves presented in Supplementary file (S5 Fig). We found
that VCC389777 significantly stimulated the ABCG2-ATPase activity, while three compounds,
VCC389777, VCC979812, and VCC450822 had a well measurable stimulatory effect on the
ABCB1-ATPase activity, suggesting the active transport of these compounds. Compound
VCC450822 showed a slight stimulation of the ABCB1-ATPase activity at lower concentra-
tions, while strongly inhibited ATPase activity at higher concentrations. This behavior is typi-
cal for slowly transported substrates and/or inhibitors of the transporters [33].
Transport assay results. The selected Vichem compounds were further characterized in
whole cell transport assays. In these experiments we used transporter-overexpressing human
Fig 2. Effects of the Vichem MtTopo-I inhibitors on the ATPase activity of the human ABCG2 and ABCB1 transporters. Purified Sf9
membrane vesicles containing ABCG2 (Upper panels, A and B) or ABCB1 proteins (lower panels, C and D) were used in ATPase assays as
described in the Methods section. Vanadate sensitive (ABC transporter related) ATPase activities were measured in the presence of
investigated MtTopo-I inhibitors. Compound identity numbers are shown in the Figure. For the sake of visibility, compounds were divided
into two groups. At zero compound levels, basal ATPase activity of the ABC transporter, measured without the addition of any drug, is shown.
Quercetin (for ABCG2) and verapamil (for ABCB1) were used as reference substrates that are known transported substrates and activate the
ATPase activity of the given transporter.
https://doi.org/10.1371/journal.pone.0202749.g002
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PLB cells and measured the uptake of various fluorescent substrates of ABCG2 and ABCB1.
This type of transport assays is commonly used to explore potential transporter-drug interac-
tions. We found that, except for VCC891909, all the compounds analyzed showed significant
interactions with ABCG2 and/or ABCB1 (Fig 3). VCC450327 was found to only moderately
influence the ABCG2 mediated transport, while having no effect on ABCB1 mediated
transport.
Toxicity of the selected Vichem compounds in human cells
Toxicity was evaluated by using several human cell lines. HFF (human foreskin fibroblast) and
HEK293 cells are non-tumor cell lines, whereas A431 cells are derived from a carcinoma. To
examine the potential influence of ABC transporters on the human cell toxicity of the investi-
gated compounds, we have also applied ABCB1- and ABCG2-overexpressing A431 cell lines.
Irinotecan, a known human topoisomerase inhibitor was used as a reference compound, as
this drug is a transported substrate of both ABCG2 and ABCB1 [34].
Table 3 shows that VCC891909 has no toxicity in any of the investigated cell lines, but the
other investigated compounds showed variable toxicity. VCC480522, VCC340963 and
VCC478498 were toxic (with IC50 values below 5 μM) in the parental A431 and HFF cells, but
Fig 3. Effects of the Vichem MtTopoI inhibitors on the transport activity of human ABCG2 and ABCB1 transporters. Effects of the
compounds on the transport activity of human ABCG2 and ABCB1 proteins were measured in transporter-overexpressing human PLB cells.
Accumulation of transporter-specific probe substrates (Calcein-AM for ABCB1 and DCV for ABCG2) was measured in the presence of MtTopo-
I inhibitor compounds (5 μM). The relative inhibitory effects of MtTopo-I inhibitors were determined by using a reference substrate, providing
maximum inhibition (20 μM verapamil or 5 μM reversin 121 for ABCB1; and 5 μM Ko143 or 5μM quercetin for ABCG2). Compounds
VCC979812 and VCC38977 were not compatible with the DCV uptake assay. In these cases (columns with sparse pattern on the figure) ABCG2
transport inhibition was characterized by inhibition of mitoxantrone extrusion, measured after 20 minutes of incubation in the same cell types
with the same reference inhibitors. Relative inhibition values higher than 0.2 are statistically significant, based on comparison to control (0) level,
by the Student’s t-test (p<0.05).
https://doi.org/10.1371/journal.pone.0202749.g003
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no difference was observed in the toxicity or the IC50 values between the parental and ABCB1
or ABCG2 expressing A431 cells (Table 3).
Discussion
The increasing number of drug resistant TB cases provides a strong incentive to find new,
effective antituberculotic agents, potentially avoiding bacterial drug-resistance. Targeting
MtTopo-I, an essential and unique mycobacterial DNA repair enzyme offers a promising pos-
sibility in this regard [22]. The docking of candidate inhibitor molecules in the recently
described crystal structure of MtTopo-I [24] may help to design new antibacterial agents.
Since imipramine and clomipramine were shown to be MtTopo-I inhibitors, these molecules
served as model drugs for in silico docking studies [18]. A compound library of Vichem was
screened by such docking studies, and a selected set of compounds was characterized in bio-
logical assays [18]. In this paper we show a detailed biological characterization of seven prom-
ising topoisomerase inhibitors, selected from Vichem compounds, designed with three
different scaffolds.
Optimization of the screening of designed antimycobacterial topoisomerase inhibitor com-
pounds, in addition to the investigation of the antimycobacterial effect, involves steps to find
molecules that have limited toxicity in mammalian cells, and a known pattern of human ABC
multidrug transporter interactions. Human ABC multidrug efflux transporters are expressed
in major tissue barriers and in numerous cell types, including macrophages, thus these trans-
porters significantly modulate ADME-toxicity profiles and cellular effectiveness for a wide
variety of drugs [33, 35]. The human ABCG2 and ABCB1 proteins are the key multidrug
transporters which have been documented to significantly reduce the cellular uptake and
modulate the ADME-Tox parameters of various antibiotics and topoisomerase inhibitors [35].
If a drug candidate is an efficiently transported substrate of these proteins, this generally
reduces the oral bioavailability (i.e. intestinal absorption) and the cellular entry of the mole-
cule. In contrast, an inhibitory effect on these drug transporters may facilitate both the absorp-
tion and cellular availability of the given compound, as well as that of other, co-administered
antimicrobial agents.
Table 3. Cytotoxicity of the selected MtTopoI inhibitor compounds in human cell lines.
Identifier Toxicity in
HFF cell line cell
line,
IC50 (μM)
Toxicity in
HEK293 cell line cell line, IC50
(μM)
Toxicity in parental A431 cell line, IC50
(μM)
Resistance
modulation
by ABCB1
(fold increase in IC50)
Resistance
modulation
by ABCG2
(fold increase in IC50)
VCC891909 Non-toxic+ Non-toxic Non-toxic NA NA
VCC979812 Toxic, 20 Non-toxic Toxic, 19±2 1.1±0.08 1±0.1
VCC389777 Non-toxic Non-toxic Non-toxic NA NA
VCC450327 Non-toxic Non-toxic Non-toxic NA NA
VCC450822 Toxic, 2.5–5 Toxic, 10–20 Toxic, 3.5±0.2 0.97±0.05 1.0±0.03
VCC340963 Toxic, 2.5–5 Toxic, 10–20 Toxic, 3.23±0.4 0.77±0.3 0.9±0.32
VCC478498 Toxic, 2.5–5 Toxic, 10–20 Toxic, 3.03±0.61 0.88±0.06 0.79±0.14
Irinotecan Non-toxic Toxic, 2.5 Toxic, 8.6±0.5 2.60±0.01 4.12±0.16
 NA: Not applicable
Cytotoxicity of the compounds was measured in a 72-hours assay in the presence of the indicated compounds. Viability was assessed using the Presto blue1 assay.
Irinotecan was used as a reference compound. IC50 values presented in the table are determined from dose-response viability curves (not shown). Compounds were
tested from 20 μM down to 3 nM. Non-toxic phrase in the table means that the compound is not toxic up to 20 μM.
https://doi.org/10.1371/journal.pone.0202749.t003
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In order to explore the direct human cellular toxicity of the selected Vichem compounds,
here we used two non-tumor cell lines (HFF and HEK293) and the A431 tumor cell line. A431
is a rapidly growing cell type with known sensitivity to topoisomerase inhibitors. In addition,
we also examined drug-resistant derivatives of this cell line to show the potential role of
ABCB1 and ABCG2 transporter in toxicity. We found that, although the antimycobacterial
effects were promising, some of the Vichem compounds examined here were toxic in at least
one of the examined cell line, with IC50 values below 5 μM. Therefore, these compounds prob-
ably cannot be considered as promising candidates for in vivo human applications.
For further selection of drug candidates, we examined the selected Vichem compounds for
ABC transporter interaction in multiple in vitro assays (summarized in S6 Fig), aiming for the
selection of lead compounds with favorable transporter interaction pattern. In the ATPase
activity assay for ABCG2 and ABCB1 transporters, in concentrations of 0.1–10 μM, several
compounds (VCC389777 for ABCG2, and VCC38977, VCC450822, VCC979812 for ABCB1)
slightly increased the ATPase activity of either the ABCG2 or ABCB1 protein, indicating that
these compounds are likely recognized as transported substrates. In contrast, for ABCG2 in
some cases (VCC478498) we obtained only an inhibition of the ATPase activity at high
(50 μM) concentrations, and some of the compounds had no measurable effect on the trans-
porter ATPase activity (VCC891909, VCC340963).
In the direct ABC transporter inhibition assays, providing increased sensitivity but without
information about the type of interaction, we found that most of the examined compounds
strongly inhibited both ABCG2 and ABCB1 mediated transport of a model compound at con-
centrations around 5 μM. VCC891909 had no such transporter inhibitory effect, while
VCC450327 had only a slight effect at 5 μM, and only on the ABCG2 transporter. It is worth
mentioning that when we used the drug-resistant, ABCB1 or ABCG2 expressing A431 cell
lines, we did not find any significant modulation of the toxicity profiles by these ABC trans-
porters. This finding suggests that the Vichem compounds are slowly transported compounds
or rather ABC transporter inhibitors—it should be mentioned that none of these assays clearly
distinguish transported substrates and inhibitors, as slowly transported substrates have inhibi-
tory effects at higher concentrations.
Taken together, our data show that VCC979812, VCC450822, VCC340936 and VCC478498
showed interactions with the human ABC transporters, while these compounds were not effi-
ciently extruded by these transporters. VCC891909 had no toxicity in any of the investigated
cell lines (HFF, HEK293 and A431). Three other compounds (VCC891909, VCC450327 and
VCC389777) were non-toxic in human cells, while may act as direct transporter inhibitors (see
S5 Fig).
As a summary, although VCC450822, VCC340963 and VCC478498 effectively inhibited
the growth of H37Rv mycobacteria, these compounds were toxic in human cell lines, thus may
not be candidates for further human drug development. This toxicity was not significantly
affected by the expression of the ABC multidrug transporters. In contrast, VCC891909 showed
efficient topoisomerase inhibition, Mtb growth inhibitory effect, and no mammalian cell toxic-
ity without a significant human ABC transporter interaction. Therefore, this compound may
be an especially favorable candidate for further antimycobacterial drug development.
Supporting information
S1 Fig. Chemical synthesis scheme of the selected Vichem compounds. The synthetic route
of the VCC891909, VCC979812 and VCC450327 is described in WO2002094796 patent (as
examples 63, 194 and 369).
(PDF)
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S2 Fig. Docking of topoisomerase inhibitors in the crystal structure 5D5H (PDB ID) of Mt
Topo-I. 2D structures highlight the key interactions.
(PDF)
S3 Fig. Representative pictures for DNA relaxation assay results presented in Table 2.
(PDF)
S4 Fig. Toxicity of the investigated compounds in H37Rv Mtb strains.
(PDF)
S5 Fig. Effects of the Vichem MtTopo-I inhibitors on the ATPase activity of the human
ABCG2 and ABCB1 transporters.
(PDF)
S6 Fig. Summary table for the results of the assays.
(PDF)
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